Guanylate cyclase recombinant

PKG and cyclic nucleotide phosphodiesterases (PDEs) (reviewed by Baxter37). A rapid release of natriuretic peptides and induction of their de novo synthesis occurs in myocardial ischemia. Natriuretic peptides may have a cardioprotective role. BNP-32 administration in perfused rat hearts prior to left main coronary artery occlusion and until 30 min of reperfusion resulted in limitation of infarct size in a concentration dependent manner. Furthermore, this effect was abolished by 5-hydroxydecanoate (presumed to be a selective blocker of mitochondrial KATp channels), L-NAME, an inhibitor of NOS and ODQ, a specific soluble guanyl cyclase inhibitor.38 Similarly, human recombinant ANP limited infarct size and reperfusion arrhythmias in a canine model of coronary occlusion and reperfusion.39... 

Nesiritide recombinant human B-type natriuretic peptide (rh BNP) used intravenously. The aid name was ANF. ANF receptors have guanylate cyclase activity, and nesiritide stimulation of die receptor T concentrations of cGMP, relaxing smooth muscles of veins and arteries. Nesiritide is used in decompensated CHF patients who have dyspnea at rest or with minimal... 

---